CN106310046A - Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma - Google Patents

Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma Download PDF

Info

Publication number
CN106310046A
CN106310046A CN201610897450.4A CN201610897450A CN106310046A CN 106310046 A CN106310046 A CN 106310046A CN 201610897450 A CN201610897450 A CN 201610897450A CN 106310046 A CN106310046 A CN 106310046A
Authority
CN
China
Prior art keywords
parts
chinese medicine
radix
breast
hysteromyoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610897450.4A
Other languages
Chinese (zh)
Inventor
李奕洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610897450.4A priority Critical patent/CN106310046A/en
Publication of CN106310046A publication Critical patent/CN106310046A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/808—Scrophularia (figwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese medicine compound for treating cystic hyperplasia of the breast and hysteromyoma. The traditional Chinese medicine compound comprises the following components in parts by weight: 8-15 parts of pseudo-ginseng, 10-20 parts of garden burnet, 10-20 parts of red paeonia, 10-20 parts of scutellaria baicalensis, 15-25 parts of selfheal, 15-25 parts of polygonum cuspidatum, 8-15 parts of rheum officinale, 10-20 parts of sophora flavescens, 10-20 parts of radix scrophulariae, 15-25 parts of poria cocos, 10-20 parts of clovershrub and 25-35 parts of oysters. The traditional Chinese medicine compound for treating cystic hyperplasia of the breast and hysteromyoma provided by the invention is capable of achieving the purpose of treating cystic hyperplasia of the breast by directing at the clinical characters of cystic hyperplasia of the breast, utilizing the drug synergism of promoting blood circulation to remove blood stasis, clearing and activating the channels and collaterals, regulating qi and blood, tonifying the spleen and smoothing the liver, utilizing the regression resistance, hyperplasia resistance and fiber modification resistance, regulating internal secretion and recovering ovarian function. The traditional Chinese medicine compound has the advantages of quick effectiveness, obvious effect, high safety, no side effect, and the like.

Description

A kind of Chinese medicine composition treating mastopathia and hysteromyoma
Technical field
The present invention relates to a kind of Chinese medicine composition treating mastopathia and hysteromyoma, belong to biomedical skill Art field.
Background technology
Mastopathia belongs to breast duct and glandular lobule regression, is 30～the frequently-occurring disease of 50 years old women, often involves double Breast, full milk, and it is more rare to be locally limited to single newborn or a certain position, morbidity and ovarian dysfunction, i.e. lutein secretion reduces female Hormone amount increases relevant relatively, and predominantly conduit capsule expands, and the fibrous tissue of ductal epithelium papillary hyperplasia and lobule increases Raw, the blister cavities formed without peplos differs in size, and includes yellow green, brown, courageous and upright one-tenth colorless slurry, and the overwhelming majority belongs to does not accompanies The simple cystic dilatation of skin hypertrophy, minority companion epithelial dysplasia person has certain probability that cancerates.
Doctor trained in Western medicine thinks what lump increased rapidly at present, or the opinion operative treatment that epithelial hyperplasia is active, or uses sharp Element testosterone propionate treatment；But effect is undesirable, operative treatment is big on psychology and normal physiological impact, and Most patients is unwilling Accept.The primary disease traditional Chinese medical science is referred to as ' nodules of the breast ' depression of liver-QI, Chong and Ren channel disorder amphitypy, uses oral medicinal herb or external application for curing, with slow Solving pain, reducing until eliminating lump.But due to endo-medicine such as RUPIXIAO, RUKUAIXIAO, XIAOYAO POWDER etc., long-term taking is to gastrointestinal Stimulate and be difficult to more greatly adhere to, and effect is undesirable.
Therefore, the Chinese herbal treatment mastopathia of exploratory development determined curative effect has the clinical meaning of reality.
Summary of the invention
For solving the problems referred to above, the present invention provides a kind of Chinese medicine composition treating mastopathia and hysteromyoma Thing.
The present invention is realized by following technical proposal: a kind of Chinese medicine composition treating mastopathia and hysteromyoma Thing, is made up of the component of following masses part:
Radix Notoginseng 8～15 parts, Radix Sanguisorbae 10～20 parts,
Radix Paeoniae Rubra 10～20 parts, Radix Scutellariae 10～20 parts,
Spica Prunellae 15～25 parts, Rhizoma Polygoni Cuspidati 15～25 parts,
Radix Et Rhizoma Rhei 8～15 parts, Radix Sophorae Flavescentis 10～20 parts,
Radix Scrophulariae 10～20 parts, Rhizoma Smilacis Glabrae 15～25 parts,
Radix Campylotropis Hirtella (Herba Myrsines Africanae) 10～20 parts, Concha Ostreae 25～35 parts.
Wherein, Radix Notoginseng: nature and flavor: hardship sweet, micro-, temperature；Function: eliminating stasis to stop pain, subduing swelling and relieving pain.Radix Sanguisorbae: nature and flavor: bitter, sour, micro- Cold；Function: cooling blood for hemostasis, astringing to arrest diarrhea, heat-clearing and toxic substances removing.Radix Paeoniae Rubra: nature and flavor: bitter；Function: dissipating blood stasis blood, clearing away heat from blood.Radix Scutellariae: nature and flavor: Bitter, cold；Function: clearing away damp-heat, pathogenic fire purging, removing toxic substances, antiabortive.Spica Prunellae: nature and flavor: bitter, acrid, cold；Function: relieve inflammation or internal heat, eliminating stagnation, detumescence.Tiger Cane: nature and flavor: micro-hardship, micro-cool；Function: analgesic therapy of invigorating blood circulation, eliminating damp-heat, relieving cough and resolving phlegm.Radix Et Rhizoma Rhei: nature and flavor: bitter, cold: function: removing the relative excess Stagnant, clots absorbing hot, lower, removing toxic substances.Radix Sophorae Flavescentis: nature and flavor: bitter, cold；Function: heat clearing away, dampness, parasite killing.Radix Scrophulariae: nature and flavor: sweet, bitter, be slightly cold； Function: nourishing YIN to lower pathogenic fire, refreshing and detoxicating.Rhizoma Smilacis Glabrae: nature and flavor: sweet, light, flat；Function: heat clearing away, dehumidify, detoxify.Radix Campylotropis Hirtella (Herba Myrsines Africanae): nature and flavor: Micro-hardship, temperature；Function: promoting blood flow to regulate menstruation, hemostasis, pain relieving.Concha Ostreae: nature and flavor: sweet, be slightly cold；Function: tranquillization with heavy prescription, YANG hyperactivity suppressing nourishing YIN, softening the hard mass Eliminating stagnation.Each composition of the present invention is national corporation of medical herbs commercially available prod.
The above-mentioned Chinese medicine composition that the present invention provides is decocted in water for oral dose routinely, it is also possible to pharmaceutical methods makes other routinely Dosage form, as being made into pill, powder, electuary, capsule etc..
Advantage that the present invention possesses and effect: treatment mastopathia that the present invention provides and the Chinese medicine of hysteromyoma Compositions can be the characteristics of incidence for mastopathia, use have blood circulation promoting and blood stasis dispelling, dredge the meridian passage, QI and blood regulating, The drug synergism of invigorating the spleen and relieving depression of liver-QI, by anti-regression, anti-proliferate, fibrosis, endocrine regulation and recovery ovarian function And reach to treat the purpose of mastopathia.Clinical effectiveness also show the Chinese medicine composition of the present invention to mammary gland fiber gland Lump in breast and hysteromyoma that tumor, cyclomastopathy, mastitis produce have significant curative effect.The treatment breast capsule that the present invention provides Property sick and hysteromyoma the Chinese medicine composition of hypertrophy early metaphase patient can be made to cure within February.This Chinese medicine composition has and takes effect The advantage such as hurry up, effect is obvious, safety is high, have no side effect.
Detailed description of the invention
Below by embodiment, the present invention will be further described.
Embodiment 1
Treatment mastopathia and the Chinese medicine composition of hysteromyoma, be made up of the component of following masses part:
Radix Notoginseng 10 parts, Radix Sanguisorbae 15 parts,
Radix Paeoniae Rubra 15 parts, Radix Scutellariae 15 parts,
Spica Prunellae 20 parts, Rhizoma Polygoni Cuspidati 20 parts,
Radix Et Rhizoma Rhei 10 parts, Radix Sophorae Flavescentis 15 parts,
Radix Scrophulariae 15 parts, Rhizoma Smilacis Glabrae 20 parts,
Radix Campylotropis Hirtella (Herba Myrsines Africanae) 15 parts, Concha Ostreae 30 parts.
Embodiment 2
Treatment mastopathia and the Chinese medicine composition of hysteromyoma, be made up of the component of following masses part:
Radix Notoginseng 8 parts, Radix Sanguisorbae 10 parts,
Radix Paeoniae Rubra 10 parts, Radix Scutellariae 10 parts,
Spica Prunellae 15 parts, Rhizoma Polygoni Cuspidati 15 parts,
Radix Et Rhizoma Rhei 8 parts, Radix Sophorae Flavescentis 10 parts,
Radix Scrophulariae 10 parts, Rhizoma Smilacis Glabrae 15 parts,
Radix Campylotropis Hirtella (Herba Myrsines Africanae) 10 parts, Concha Ostreae 25 parts.
Embodiment 3
Treatment mastopathia and the Chinese medicine composition of hysteromyoma, be made up of the component of following masses part:
Radix Notoginseng 15 parts, Radix Sanguisorbae 20 parts,
Radix Paeoniae Rubra 20 parts, Radix Scutellariae 20 parts,
Spica Prunellae 25 parts, Rhizoma Polygoni Cuspidati 25 parts,
Radix Et Rhizoma Rhei 15 parts, Radix Sophorae Flavescentis 20 parts,
Radix Scrophulariae 20 parts, Rhizoma Smilacis Glabrae 25 parts,
Radix Campylotropis Hirtella (Herba Myrsines Africanae) 20 parts, Concha Ostreae 35 parts.
Take above-described embodiment gained treatment mastopathia and the Chinese medicine composition of hysteromyoma, control for following clinical Treat:
One, treatment target
Select case 30 example of mammary gland fibroadenoma, case 30 example of cyclomastopathy, case 30 example of mastitis, mammary gland long-pending breast pus Swollen case 30 example, case 30 example of breast carcinoma, case 30 example of hysteromyoma, the age is 30～60 years old.
Above-mentioned all kinds of cases are bisected at random treatment group and matched group, each 90 examples.
Two, usage
Treatment group be decocted in water for oral dose the various embodiments described above provide Chinese medicine composition, decoction every day 1 dose, 3 times on the one, serve on February and carry out Observe.
Matched group takes RUPIXIAO, RUKUAIXIAO, XIAOYAO POWDER etc. routinely, observes February.
Three, result
The treatment mastopathia of present invention offer and the Chinese medicine composition clinical therapeutic efficacy of hysteromyoma:
Treatment group reaches 100% to the effective percentage of mammary gland fibroadenoma, obvious effective rate is 95%, clinical cure rate is 87%；To cyclomastopathy Effective percentage reach 100%, obvious effective rate be 97%, clinical cure rate be 90%；The effective percentage of mastitis reaches 100%, obvious effective rate is 96%, clinical cure rate is 90%；The effective percentage of mammary gland long-pending breast abscess is reached 99%, obvious effective rate be 95%, clinical cure rate be 85%； The effective percentage of breast carcinoma is reached 90%, obvious effective rate be 93%, clinical cure rate be 20%；The effective percentage of hysteromyoma is reached 88%, shows Efficiency is 92%, clinical cure rate is 23%.And without any reactions such as gastrointestinal upsets.
And matched group reaches 53% to the effective percentage of mammary gland fibroadenoma；The effective percentage of cyclomastopathy is reached 65%；To mastitis Effective percentage reach 68%；The effective percentage of mammary gland long-pending breast abscess is reached 59%；The effective percentage of breast carcinoma is reached 32%；To hysteromyoma Effective percentage reaches 14%.
Four, conclusion
Treatment mastopathia and the Chinese medicine composition of hysteromyoma that the present invention provides can be to increase for breast capsule Sick characteristics of incidence, uses the drug synergism with blood circulation promoting and blood stasis dispelling, dredge the meridian passage, QI and blood regulating, invigorating the spleen and relieving depression of liver-QI, passes through Anti-regression, anti-proliferate, fibrosis, endocrine regulation and recover ovarian function and reach treat mastopathia mesh 's.Therapeutical effect is better than matched group.
Clinical effectiveness also show the Chinese medicine composition of the present invention and produces mammary gland fibroadenoma, cyclomastopathy, mastitis Lump in breast and hysteromyoma have significant curative effect.What the present invention provided treats in mastopathia and hysteromyoma Drug composition can make early metaphase patient cure within February.This Chinese medicine composition has instant effect, effect is obvious, safety is high, nothing The advantages such as side effect.

Claims (1)

1. the Chinese medicine composition treating mastopathia and hysteromyoma, it is characterised in that by the group of following masses part It is grouped into:
Radix Notoginseng 8～15 parts, Radix Sanguisorbae 10～20 parts,
Radix Paeoniae Rubra 10～20 parts, Radix Scutellariae 10～20 parts,
Spica Prunellae 15～25 parts, Rhizoma Polygoni Cuspidati 15～25 parts,
Radix Et Rhizoma Rhei 8～15 parts, Radix Sophorae Flavescentis 10～20 parts,
Radix Scrophulariae 10～20 parts, Rhizoma Smilacis Glabrae 15～25 parts,
Radix Campylotropis Hirtella (Herba Myrsines Africanae) 10～20 parts, Concha Ostreae 25～35 parts.
CN201610897450.4A 2016-10-15 2016-10-15 Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma Pending CN106310046A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610897450.4A CN106310046A (en) 2016-10-15 2016-10-15 Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610897450.4A CN106310046A (en) 2016-10-15 2016-10-15 Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma

Publications (1)

Publication Number Publication Date
CN106310046A true CN106310046A (en) 2017-01-11

Family

ID=57817858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610897450.4A Pending CN106310046A (en) 2016-10-15 2016-10-15 Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma

Country Status (1)

Country Link
CN (1) CN106310046A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112220899A (en) * 2020-12-01 2021-01-15 云南苗心康生物科技有限公司 Traditional Chinese medicine composition for breast health care and breast collateral dredging and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105434815A (en) * 2015-12-18 2016-03-30 邓瑞萍 Drug for treatment of breast cystic hyperplasia disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105434815A (en) * 2015-12-18 2016-03-30 邓瑞萍 Drug for treatment of breast cystic hyperplasia disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
屠佑堂等: "《中医实用诊疗大全 下》", 31 March 2013, 湖北科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112220899A (en) * 2020-12-01 2021-01-15 云南苗心康生物科技有限公司 Traditional Chinese medicine composition for breast health care and breast collateral dredging and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102670961B (en) Traditional Chinese medicine for treating middle and old aged habitual constipation
CN103721080A (en) Traditional Chinese medicine composition for treating cervical spondylosis, lumbar spondylosis and sciatica
CN103784804A (en) Pharmaceutical composition for treating benign prostatic hyperplasia
CN101874850B (en) Medicament for treating chronic urticaria
CN103610854A (en) Traditional Chinese medicine (TCM) for treating allergic rhinitis
CN102512516B (en) Medicinal moxa roll for treating mammary gland tumors and preparation method thereof
CN106310046A (en) Traditional Chinese medicine compound for treating cystic hyperplasia of breast and hysteromyoma
CN104001131A (en) Oral traditional Chinese medicine for preventing and treating stress ulcers
CN102078432A (en) Medicament for treating skin itch
CN106075265A (en) The Chinese medicine composition for the treatment of viral influenza
CN101239140A (en) Chinese medicine for treating psoriasis
CN104383064A (en) Formula of Chinese herbal medicine for treating cervicitis
CN104001100A (en) Traditional Chinese medicine composition for treating PICC (Peripherally Inserted Central Catheter) phlebothrombosis and preparation method of traditional Chinese medicine composition
CN103690833B (en) A kind of Chinese medicine for the treatment of rheumatic arthritis
CN103736013B (en) One treats phthisical Chinese medicine
CN102614432B (en) Traditional Chinese medicine composition for treating cervicitis
CN107456551A (en) A kind of Chinese medicine for treating gastritis
CN101983676A (en) Medicament for treating gynecological blood stasis and qi stagnation
CN105687584A (en) Traditional Chinese medicine for treating thyroid cancer and preparing method of traditional Chinese medicine
CN105617223A (en) Medicine for treating thyroid cancer
CN105920541A (en) Traditional Chinese medicinal composition for treating tinea versicolor
CN103110852B (en) Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof
CN104306530A (en) Traditional Chinese medicine used for treating prolapse of lumbar intervertebral disc
CN103768366B (en) Traditional Chinese medicine preparation for treating proliferation of mammary gland
CN110141626A (en) A kind of patch and preparation method thereof for treating mammary gland disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170111